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Abstract 
THE EFFECTS OF ORAL CONTRACEPTIVES ON MOOD AND AFFECT: A META-
ANALYSIS 
 
Erica Motter 
 
Combined oral contraceptive (COC) pills are widely used by women of reproductive age, 
but there is still little conclusive evidence that exists about the mood-related side effects 
associated with their use. This meta-analysis examined the relationship between oral 
contraceptive use and mood effects such as depression and anxiety to determine what 
role, if any, that COCs may have in the worsening or improvement of women’s mood 
when taking them. Effect sizes compared the differences in women’s mood scores before 
taking COCs and after one or more cycles of use. Seventeen studies made up of 25 
individual samples contributed 71 effect sizes for this analysis. The results suggest that 
COCs tend to contribute to a small but significant improvement in women’s overall 
moods. However, methodological challenges and inconsistencies make it difficult for 
researchers to establish any firm conclusions about the role COCs play in mood changes. 
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Introduction 
Reproduction is a function that all living creatures perform, but it is not always 
something they can control in terms of timing or prevention. Like any species, human 
beings are motivated by an innate need and desire to reproduce, but unlike other species, 
modern humans have gained the ability to control if and when we reproduce to a very 
high degree through the use of various contraceptive methods. Some more basic forms of 
contraception, such as condoms, have provided humans with the ability to prevent 
unwanted pregnancies by creating a mechanical barrier between male and female 
reproductive cells. But as human science and medicine have advanced, humans have now 
reached a point at which women are able to influence the reproductive functions of their 
bodies by chemical means--by disrupting the natural fluctuations of hormones within 
their bodies to harness the timing of a natural menstrual cycle. The result of this is that 
women now simply can take pills to dictate whether or not they ovulate, as well as to 
interrupt and tame their natural menstrual cycles at will. 
While the development of combined oral contraceptive pills (COCs) has granted 
women a greater degree of sexual and personal freedom (Bailey, 2006; Traulsen, 
Haugbølle, & Bissell, 2003), there are still many aspects of hormonal contraception that 
remain mysterious to both pharmaceutical researchers and the women who take COCs. 
Although research has sought to examine some of the short and long-term effects of 
COCs on women’s physical experiences as well as emotional experiences, there is still 
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much to be studied about the multitude of ways COCs could impact women’s health and 
lives.  
Combined Oral Contraceptives: An Overview 
Hormones in the body perform a variety of functions related to reproduction, 
behavior, and development. The levels of different hormones circulating in a human 
body, as well as the timing of their production and release, combine to orchestrate many 
physical changes and behavioral motivations related to survival and reproduction. The 
production and release of hormones are regulated by the hypothalamic-pituitary-ovarian 
axis (HPO axis) in women, which sends signals in the form of “releasing hormones” from 
the hypothalamus to the ovaries to trigger the production of sex hormones such as 
estrogens and progestogens. Estrogens, often thought of popularly, and incorrectly, as the 
“female” hormone(s) (this is incorrect since men also produce estrogen), are one class of 
many endogenous hormones, and are divided into three common types: estrone (E1), 
estradiol (E2), and estriol (E3). A fourth type of estrogen, estetrol (E4) is only produced 
during pregnancy. Estrogens play a role in orchestrating behavioral motivation and bodily 
development by coordinating a natural menstrual cycle in organisms. Progestogens, such 
as progesterone, are types of steroid hormones that bind to progesterone receptors in the 
body, influencing other aspects of reproduction such as cervical mucus thickness and 
ovular release.  
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A natural menstrual cycle lasts around 28 days and consists of several distinct 
phases. The first phase of the cycle begins during bleeding, when levels of both estrogen 
and progesterone are low in the body. The pituitary gland then releases follicle-
stimulating hormone (FSH) and a rise in estrogen levels occurs steadily during the next 
phase of the cycle, called the follicular phase, as immature egg follicles grow in the 
ovaries. Around day 14 of the cycle, a surge in luteinizing hormone (LH) triggers the 
release of the mature egg follicle and the corpus luteum forms at the release site, as the 
body enters the luteal phase of the cycle. The corpus luteum releases high levels of 
progesterone but is only a temporary structure, and without egg implantation, it will 
begin to recede as the cycle draws to its close. At the end of the cycle, both estrogen and 
progesterone levels decline dramatically, triggering menstruation and beginning a new 
cycle. 
A combined oral contraceptive pill consists of two main components: a synthetic 
form of estrogen and a synthetic progestogen, called a progestin. These synthetic 
hormones block the natural activities of the HPO axis by means of a negative feedback 
loop--that is, the high levels of exogenous hormones signal to the pituitary that it does not 
need to produce FSH or LH in accordance with a natural cycle. Almost all COCs utilize 
the synthetic estrogen called ethinyl estradiol (although a few COCs utilize a less-
common synthetic estrogen called mestranol) to artificially influence levels of estrogen in 
a female body and adjust a woman’s menstrual cycle in accordance with a defined dosage 
schedule. There are numerous classes and generations of synthetic progestogens, called 
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progestins, that are combined with ethinyl estradiol to create an effective and simple 
method of contraception in the form of a small pill. These COCs are taken on a daily 
basis according to a schedule--often 21 days, but sometimes 28-day or other regimens--
followed by a series of days of inert “placebo” pills, during which time women 
experience the withdrawal bleeding associated with the menstrual phase of their cycles. 
Doses of the pills may remain steady throughout the regimen, or they may be staggered in 
a “triphasic” regimen that more closely mimics the changing levels of hormones during a 
woman’s natural cycle.  
Widespread use of COCs. Thanks to the convenience and efficacy of this 
method, COCs are used more commonly than any other method of contraception (Mosher 
et al, 2004). Even if a woman does not use COCs continuously, it is still likely that she 
will use them at some point in her life. A longitudinal study found that, in a group of 
women followed over a period of 25 years, 95% of participants had used COCs as a 
method of contraception at some point during that period (Lindh, Ellstrom, Blohm, & 
Milsom, 2010). In 2004, a study investigating contraceptive use across five European 
countries found that over 22 million women used COCs as a contraceptive method, and 
that most reported high levels of satisfaction with their choice (Skouby, 2004). 
COCs and side effects. As with any pharmaceutical, there have been ongoing 
clinical trials and studies since the introduction of COCs in the 1960s, all with the goal of 
examining the positive and negative effects of COCs on both physical (cycle length, 
cramping, bleeding, breast pain, etc.) as well as emotional (depression, anxiety, mood 
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swings) and psychological (mate preferences, social behavior, sexual behavior) health. 
Although potential health-related side effects of COC use has been the focus of much 
research (reviewed in Welling, 2013), relatively little has been done regarding the 
potential emotional or psychological (reviewed in Hahn & Cobey, 2019) side effects, 
with the result being that much of the existing literature about COC use mostly addresses 
physical effects rather than emotional effects. 
 And yet, many women self-report difficulties with mood changes that occur while 
they are taking COCs. A study by Rosenberg and Waugh (1997) found that 46% of 
women who discontinue oral contraceptive use do so because of mood-related side 
effects. Women who discontinue oral contraceptive use often turn to a less effective 
method of contraception, putting them at risk for an unintentional pregnancy (Segebladh, 
Borgström, Odlind, Bixo, & Sundström-Poromaa, 2009; Skouby, 2004). As such, it is 
critical to develop a better understanding of the potential mood-related side effects that 
may or may not exist with contraceptive use. 
Examination of Literature 
 Anecdotally it is still a commonly held belief that COCs can have a negative 
effect on a woman’s mood, but the literature has struggled to find a consistent effect. 
Some studies have found that COC use actually improves mood outcomes (Nyberg, 
2013; Ott, Shew, Offner, Tu, & Fortenberry, 2008; Walker & Bancroft, 1990; Young et 
al., 2007) while others have found an overall worsening of mood (Gingnell et al., 2013, 
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Sanders, Graham, Bass, & Bancroft, 2001; Skovlund, Mørch, Kessing, & Lidegaard, 
2016). Still other studies have found individual differences in a single sample population 
- with some women experiencing improvement in mood and others experiencing negative 
mood effects when taking COCs (Graham, Bancroft, Doll, Greco & Tanner, 2007; 
Lundin et al., 2017). 
Mood improvement. Several studies have suggested that women experience an 
improvement in their mood symptoms when taking COCs compared to when not taking 
them. In 2013, an open-label prospective study using a COC containing norgestimate 
showed a significant improvement in negative mood symptoms compared to placebo for 
women who had been experiencing severe premenstrual symptoms before treatment 
(Nyberg, 2013). Another study by Ott and colleagues examined the effects of hormonal 
contraceptives on adolescents, using daily diaries and face-to-face interviews over a 
period of 41 months (Ott et al., 2008). They found that periods of stable oral 
contraceptive use correlated significantly with reports of higher positive mood and lower 
negative mood effects. A similar longitudinal study by Walker & Bancroft (1990) 
measured several factors related to contraceptive use in a sample of participants living in 
a setting with high rates of poverty and inconsistent use of birth control and found that 
COC users reported higher positive and lower negative mood during periods of use 
compared to periods of non-use. Another study by Young, et al. (2007) utilized data from 
the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study to 
compare mood symptoms across women taking COCs versus women who are not, and 
7 
 
7 
 
found reports that women on COCs reported lower incidences of depressive symptoms 
and general better functioning. 
Mood worsening. Conversely, several studies have suggested the opposite effect, 
with women experiencing negative mood side effects when they begin taking COCs. A 
double-blinded, placebo-controlled randomized trial examining changes in brain activity 
and mood in women with a history of depression found that women taking COCs scored 
higher on measures of depression, mood swings, and fatigue compared to those taking a 
placebo (Gingnell et al., 2013). Another study by Sanders and colleagues assessed 79 
women before initiating OC use and again after 3, 6, and 12 months of use (Sanders et 
al., 2001). These researchers found that 47% of the women in the study discontinued 
COC use and reported significantly higher scores of emotional side effects than women 
who continued to take them. More recently, a nationwide prospective cohort study 
conducted in Denmark examined over a million women’s hormonal contraceptive use 
and found an association between use of hormonal contraceptives and subsequent use of 
antidepressants and diagnoses of depression (Skovlund et al., 2016). 
 However, it is possible that different generations of COCs could affect women’s 
moods differently. A 2014 randomized, double-blind study compared a group of women 
taking a second-generation COC to a group taking a third-generation pill formulation 
(Shahnazi et al., 2014). The women taking the second-generation COC showed a 
decrease in positive mood and an increase in negative mood after initiation, while the 
women in the group taking the third-generation COC showed the opposite effect. 
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No effect. An additional group of studies suggest that COCs have little to no 
effect on women’s mood. A 2007 correlational study examining oral contraceptive use 
among Australian woman found that the odds of developing depression symptoms were 
not significantly different for women taking COCs compared to women who were not 
taking them (Duke, Sibbritt, & Young, 2007). A double-blind, placebo-controlled trial 
examining the side effects of COCs in adolescents also found no difference in depression 
symptoms between the experimental and placebo groups after three months of treatment 
(O’Connell, Davis, & Kerns, 2007). An observational study by Rapkin and colleagues 
also sought to find out whether depression symptoms developed in women who began 
taking a low-dose COC and were examined over the course of three months (Rapkin, 
Morgan, Sogliano, Biggio, & Concas, 2006). Despite a noted decrease in their levels of 
neuroactive steroids, which was expected to be a predictor of depression symptoms, the 
women in this study did not report any significant worsening of mood. 
Treating PMDD with COCs. Many studies have used placebo-controlled trials 
to examine the positive mood effects of COCs in women with premenstrual dysphoric 
disorder (Eisenlohr-Moul, Girdler, Johnson, Schmidt, & Rubinow, 2017; Freeman et al., 
2001; Graham & Sherwin, 1992; Pearlstein, Bachmann, Zacur, & Yonkers, 2005; Peters, 
Freeman, Kim, Cohen, & Joffe, 2017; Yonkers & Foegh, 2005; others) often utilizing a 
progestin such as drospirenone with the goal of improving premenstrual symptoms. 
 A small study examining 25 participants found that women taking a COC with 
drospirenone reported greater improvements in mood symptoms compared to the placebo 
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group (Pearlstein et al., 2005) while a follow-up study using a larger group of 328 
participants also concluded that the same COC formulation improved PMDD symptoms 
compared to controls (Yonkers & Foegh, 2005). Two open-label observational studies 
(Borges et al., 2006; Parsey & Pong, 2000) also examined the effects of a COC 
containing drospirenone. These studies both found reported improvements in mood while 
taking the COC compared to not taking it. Study outcomes included personality traits 
examining dimensions of depression and social introversion, and no difference was found 
between baseline scores and scores at completion of the study. 
 Another randomized trial was conducted in women with a history of depression 
who experience premenstrual worsening of their mood symptoms. The women in this 
study were given a COC containing drospirenone, with some participants receiving a 
placebo during the pill-free interval, but no difference was found in the ratings of 
depression between the two groups (Joffe & Petrillo, 2007). A similar study by 
Eisenlohr-Moul and colleagues, conducted ten years later, also used a COC formulation 
containing drospirenone to examine its effects on women with PMDD (Eisenlohr-Moul et 
al., 2017).  The study included administration of the COC on both continuous and 
intermittent dosing schedules, but still failed to find a significant improvement between 
the mood scores of women in those groups compared to the placebo group. 
10 
 
10 
 
Current Issues with COC Research 
 A lack of standardized research regarding COC use and mood has made it 
difficult to report overall effects among the studies that have been conducted. As 
previously stated, studies have produced conflicting results about the effects of COCs on 
mood. Researchers have not used a “standard” pill formulation, and in some cases did not 
even report or record the formulations being taken by participants. To date, there is also 
not an agreed-upon standardized scale to measure mood/affect changes related to COCs 
and mood, making it difficult to analyze the data consistently across several different 
studies. Furthermore, no published analyses have examined variables of interest that 
might contribute to the overall mood effects of COCs--variables such as pill 
formulations, dosing schedules, individual differences, or cycle timing differences. 
Lack of placebo-controlled trials in healthy women. One of the biggest barriers 
to COC research is that there is a lack of placebo-controlled trials that have been carried 
out in healthy women, as they were long considered infeasible. For many years, it was 
believed that placebo-controlled trials could only be carried out using sterilized women, 
due to the chances of placebo-group participants becoming pregnant during their research 
participation. The result is that few examples of placebo-controlled trials using healthy 
women exist. 
Use of different pill formulations. It is very difficult to draw conclusions about 
COCs in a general way when so many different formulations of pills exist. COCs can 
vary in terms of the dosage of ethinyl estradiol, although the dosage typically falls 
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somewhere between 25 and 35 μg. They can also vary in terms of the type of progestin 
used, with a very large number of different types of these synthetic hormones being 
commonly used in pill formulations. Some of the more common progestins used are 
desogestrel, levonorgestrel, norgestimate, and drospirenone. In general, there are two 
classes of progestins: androgenic, which mimic the “masculinizing” effects of 
testosterone in the body such as heightened sex drive, acne, and hair growth; and 
antiandrogenic, which suppress these “masculinizing” activities. The androgenic 
properties of the progestin used in a formulation of COC could contribute to individual 
differences in responses to birth control pills. 
 Furthermore, some oral contraceptives are administered in a monophasic regimen, 
in which the active pills all contain the same doses of ethinyl estradiol and progestin, 
while others are administered in a triphasic regimen with doses of the hormones changing 
throughout the three active weeks of the cycle. Most COCs are administered according to 
a 21/7 dosing schedule (21 active days and 7 “bleeding” days) but some follow a 24/4 or 
extended regimen with a longer period of active pill days.  
 In light of these differences in both the specific synthetic progestin used, variation 
in the dosage (of both estrogen and progestin), and variation in the administration 
schedule across different brands of the combined oral contraceptive pill, collapsing data 
from all ‘pill users’ into a single, homogenous group may present a significant design 
concern. A large-scale study of COC use in the US recently demonstrated that women 
aged 15-44 report using over 80 different brands of COCs (Hall & Trussell, 2012). In this 
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sample of over 12,000 women, high-dose estrogen pills were more common than low-
dose, 58% of women used a COC with an older generation progestin, and two-thirds used 
monophasic pills. This study highlights the importance of considering the specific COC 
used in future research, and of the need for within-participant research examining the 
potential differential impact of different COCs. 
 Despite the spectrum of pills that all fall under the umbrella of COCs, many 
studies have not sought to distinguish between these formulations when collecting data 
about women’s mood symptoms and COC use (Skovlund et al., 2016; Sulak, 2000). In 
order to gain a large enough sample for a study, researchers may choose to forego the 
difficulty of obtaining information about individual formulations of pills and instead 
simply ask about general COC use. While this is understandable, it can make it difficult 
for researchers to draw nuanced conclusions about differences between types of COCs 
and effects on mood. 
The survivor effect. Another difficulty when conducting research about COCs is 
that there is a high likelihood of biased reporting due to a “healthy survivor” effect. 
Women who participate in studies examining COC use will often drop out of the study if 
they experience severe adverse effects while taking the pills (Oinonen & Mazmanian, 
2001). This can present a challenge when researchers examine the study’s final data, 
since the experiences of the women who left the study cannot be properly assessed. 
 For example, a 2008 longitudinal study by Berenson and colleagues found that 
COCs provided a protective effect against nervousness and mood swings that persisted 
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for two years after follow-up for both an injectable form of COC as well as a 20 μg 
ethinyl estradiol formulation, when comparing factors across a range of users and using 
the Beck Depression Inventory as a measure of mood symptoms. (Berenson, Odom, 
Breitkopf, & Rahman, 2008). This outcome suggests that COCs contribute to the 
improvement of women’s moods while taking them. However, the researchers also 
noticed that the greatest number of participants lost to follow-up were ones who had 
reported negative mood effects such as nervousness, depression, or loss of energy in the 
initial phases of the study. This “survivor effect” can cast doubt on the results of studies, 
since they typically only report the scores from women whose mood symptoms while 
taking COCs were mild enough to continue use long enough to complete the study. 
Use of different scales to measure mood. While there have been many studies 
utilizing self-reports of mood or observer ratings to assess mood changes, there has not 
been a consistent scale used across COC mood studies. Many different types of scales 
have been used across various studies to measure changes in mood associated with COC 
use, with the result being that it is difficult to know whether differences in mood changes 
are due to actual drug effects or simply measurement differences. 
 Studies assessing women with PMDD have utilized the Daily Record of Severity 
of Problems (DRSP), which is a standard scale used to diagnose PMDD in women 
(Lundin et al., 2017; Yonkers & Foegh, 2005). This scale is useful because it involves 
mood tracking across a woman’s cycle, and since it measures a wide range of symptoms 
related to premenstrual syndromes. Other studies have used standard scales that chiefly 
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measure depression symptoms, such as the Beck Depression Inventory (BDI) or the 
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) to measure mood 
changes related to COC use (Graham et al., 2007; Greco, Graham, Bancroft, Tanner, & 
Doll, 2007). Still others have utilized a self-made questionnaire or a combination of 
scales to measure mood changes (Joffe, Cohen, & Harlow, 2003; Sanders et al., 2001). 
 There has been a noteworthy difference found between studies utilizing a 
retrospective method (reporting from memory of past days) of mood reporting as 
compared to a prospective (reporting on a current day’s state) rating of mood. Studies 
asking women to retrospectively report mood changes related to COC use generally 
found that women report a more extreme worsening of mood while using COCs than 
studies asking women to use prospective reports (Oddens, 1999; Joffe et al., 2003). 
Conversely, studies that required women to track their mood each day prospectively often 
found improvements in mood over time (Lundin et al., 2017; Rebollar, Balaña, & Pastor, 
2017). Prospective ratings of mood have come to be seen as more reliable reports, but 
unfortunately, many studies have only utilized retrospective reports of mood changes. 
 One of the biggest challenges to measuring mood is that the subjective experience 
of “mood” itself is often difficult to define. Some researchers have moved away from 
simple scales of improvement/worsening and have begun to discuss mood in terms of 
dimensions of affect instead. They have found it useful to distinguish between “positive 
affect” and “negative affect” which can both change independently of each other or be 
individually subject to higher levels of variability. A scale called the Positive and 
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Negative Affect Schedule (PANAS) has been used in a couple of studies to measure these 
dimensions of affect (Jarva & Oinonen, 2006; Rebollar et al., 2017). The scale asks 
participants to rate the extent to which they feel a number of different emotions currently 
or within the past week on a 1 to 5 scale--including both positive and negative emotions. 
Using this scale, researchers were able to report results in terms of affect variability, and 
it was found in one study that COC use was associated with positive affect stabilization 
(Jarva & Oinonen, 2006). It is possible that use of a more nuanced scaled such as the 
PANAS could help to clear up the confusion in some studies that simply measured mood 
in terms of improvement or worsening, but at present the research is still divided by use 
of different scales. 
Meta-analysis: A way to organize the outcomes. In light of the widespread 
inconclusiveness of results in this field of research, a meta-analysis is a useful way to 
shine a light on possible connections between variables that interact with birth control use 
and mood, and to direct future research toward examining the most likely possibilities for 
explaining these connections. Organizing and standardizing the data from several studies 
helps to uncover any patterns that may exist in the overall effect of COC use. 
Method 
After examining the existing research related to COCs and their effects on mood, 
a protocol for the meta-analysis was developed and pre-registered on the Open Science 
Framework (https://osf.io/4wfeq/), outlining the goals and methods for the project. Since 
this research was utilizing data drawn from human subjects, Institutional Review Board 
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(IRB) approval to conduct the study was obtained on March 26, 2018 (IRB 17-184) by 
the Humboldt State University IRB. 
Following PRISMA guidelines, the major steps required were outlined as follows: 
searching for papers based on literature review findings, searching for papers according 
to keywords using several databases, excluding duplicates obtained during the searches, 
excluding papers from the sample based upon a set of predetermined exclusion criteria, 
organizing all of the papers that were not excluded, reading through each paper to record 
statistics and variables of interest, contacting authors to attempt to obtain statistics that 
were missing or reported in an unusable format, standardizing all of the statistics from 
different scales into uniform effect sizes, and finally running the meta-analysis on these 
statistics to find an overall effect. 
Location of Papers 
Literature review. The majority of the papers included in this meta-analysis were 
found using the reference sections of published articles related to COC use and mood. 
These were located during a literature review and recorded in a table, and then screened 
to determine which ones qualified for inclusion in the meta-analysis. A total of 58 papers 
were examined, and 23 of those papers met the criteria for inclusion in the meta-analysis. 
The others were excluded mostly due to their methodologies, as they were not within-
subjects trials examining the effects of COCs on women’s moods.  
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Database searching. The databases searched to locate relevant papers were 
Google Scholar, PubMed, PsycINFO, Web of Science and the Cochrane Central Register 
of Controlled Trials. To perform these searches, the keyword combinations of 
“contracept-,” “depression,” “anxiety,” “birth control,” “mood,” and  “affect,” were used 
in different configurations of AND and OR to generate the most relevant results within a 
manageable sample of papers. The last date of database searching took place on 4/24/18. 
 These searches retrieved a total of 526 papers for potential inclusion in the study. 
An examination of the retrieved papers resulted in the exclusion of the majority of them, 
mostly due to their methodologies and aims. In particular, papers retrieved from Google 
Scholar and PsycINFO were most often analyses of the social effects of contraceptives, 
rather than studies examining their physical or emotional effects. Many of the papers 
retrieved from PubMed and Web of Science focused on the physical side effects of COCs 
rather than the emotional effects (n = 447). There were 71 duplicate papers removed from 
the search results, either having been retrieved from more than one database or already 
having been retrieved during the literature review. All told, searching of databases 
contributed a total of eight additional studies to be included in the meta-analysis. 
Contacting researchers. Using the reference sections of published articles, key 
researchers in the field of COC effects were identified. These researchers were sent 
emails explaining the aims of the meta-analysis and requesting any unpublished data they 
may have. Most of the authors replied explaining that they did not have any unpublished 
data. One set of data was retrieved from a researcher at the University of Glasgow. 
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Additionally, a request for unpublished data was posted to several listservs related to this 
field but received no responses.  
Exclusion Criteria for Papers 
 In order to avoid cherry-picking data and creating potential selection effect 
confounds in the study, a list of criteria was developed for the type of papers included in 
the meta-analysis. The specifications of this list were adhered to while constructing the 
sample to ensure the broad inclusion of as many relevant papers as possible without 
compromising the integrity of the analysis. 
Methodology. Only papers that utilized a within-subjects design were included in 
the analysis, since this allowed for the examination of pre-test and post-test measures of 
mood. This reduced the possibility that an effect may only be due to individual 
differences between subjects. Ideally, the analysis would have included only randomized 
trials of COCs with a placebo, but since there were so few studies conducted using this 
methodology, this restriction would have limited the sample too much. All randomized 
trials of COCs with or without placebo that included mood symptoms as a primary or 
secondary outcome, studies comparing two or more formulations of COCs with mood 
symptoms as a primary or secondary outcome, and studies testing efficacy of COC 
formulations to treat PMDD were eligible for inclusion in the meta-analysis. This 
criterion was established in the hopes that it would allow for examination of the existing 
literature as broadly as possible without including studies likely to have confounds. 
19 
 
19 
 
Time period. The meta-analysis only included papers published from 1985 
onward. Although studies were conducted to evaluate side effects of COCs before this 
year, in 1985 there was a change in the standard level of estrogen in COCs after concerns 
about higher levels being linked to a risk of vascular disease. Since this time, doses of 
ethinyl estradiol in COCs have ranged only from 25 micrograms to 35 micrograms, 
whereas older research used doses of ethinyl estradiol encompassing a wider range. This 
timeframe choice was made with the intention that this meta-analysis only sampled data 
relevant to current practices while still encompassing a span of several decades. 
Language. In regard to language of publication, only papers available in English 
or with an English translation were included, so that they could be read and understood 
fully. 
Reporting of COC type and dosage. Although it would have been preferable to 
only include studies that reported the formulations and doses of COCs used by 
participants, this would have limited the meta-analysis sample size too much. Instead, all 
studies that adhered to the other established criteria for inclusion, even those that do not 
include specific pill brands, formulations, or doses were included in the analysis. 
Population sample. It would have been most beneficial to the study goals to 
examine data from studies only looking at healthy women of reproductive age. 
Unfortunately, not many studies have conducted placebo-controlled trials using samples 
of healthy women, as it was long believed to be unethical to perform them, due to the risk 
of pregnancy for women in the placebo group. Consequently, much of the data was 
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collected from studies utilizing a sample of women with a pre-existing condition such as 
PMDD, and some from women who were infertile. This allowed for the collection a large 
enough sample of data to perform the necessary analyses. 
Types of scales. Another criterion for inclusion is the type of scales used in the 
studies. As previously mentioned, an issue with this field of research in general is that 
studies have utilized many different types of scales. Consequently, a broad range of 
scales were included in order to avoid limiting the data. Any studies that utilized a 
standard scale with a primary or secondary outcome of mood ratings (for example the 
BDI, PANAS, Q-LES-Q, etc.) were included in the meta-analysis. A few studies that 
utilized a custom-made scale with mood improvement/worsening as a primary or 
secondary outcome were also included in the analysis. 
Data Collection and Coding 
 After the sample of papers was selected and pared down according to the 
aforementioned exclusion criteria, they were scanned to find the relevant data points to 
record. In order to find the effect sizes, there needed to be a pre-pill mood mean and 
standard deviation for the sample COC group, and a post-pill mean and standard 
deviation reported in each paper. Many papers included a few different experimental 
samples within one study (e.g. a group taking one formulation of COCs and another 
group taking a different formulation), so these were recorded as separate samples. Many 
papers also used several scales to measure the same samples, or several scale items 
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addressing different dimensions of mood. These were also recorded separately but 
classified as belonging to the same sample. For studies that included several pre or post 
measurements (often divided by cycle phase), these scores were averaged but still 
separately recorded according to samples, scales, and scale items. 
 Several of the papers that met all other criteria for inclusion did not report the 
score results in a usable format. Some reported results using only visual scales or graphs 
(Bäckström, Hansson-Malmström, Lindhe, Cavalli-Björkman, & Nordenström, 1992; 
Bancroft, Sanders, Warner, & Loudon, 1986; Deijen, Duyn, Jansen, & Klitsie, 1992; 
Graham, Ramos, Bancroft, Maglaya, & Farley, 1995; Graham & Sherwin, 1993; Parsey 
& Pong, 2000); others failed to report standard deviations (Pearlstein et al., 2005; 
Yonkers & Foegh, 2005); others reported medians instead of means (Joffe et al., 2007; 
Peters et al., 2017). The authors of these papers were contacted and asked to provide the 
data in a usable format for the meta-analysis, but only one response resulted in the 
acquisition of the necessary data. This resulted in the exclusion of nine studies from the 
final analysis, as well as secondary scale scores from two other papers. 
 Two additional papers were excluded for reporting their results in the form of 
odds ratios (Westhoff et al., 2007; Berenson et al., 2008). This decision was based on the 
idea that the overall concept behind the collection of these scores were different from the 
pre-post measurements, as they instead were aiming to find the likelihood of developing 
adverse mood symptoms when taking COCs or discontinuing use of COCs due to mood 
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symptoms, rather than comparing magnitudes of change in mood before and after 
initiation of COC use. See Figure 1 for all steps related to data exclusion. 
Calculating effect sizes. After all the data was collected from each paper, the 
effect sizes and effect size variances were calculated using an online effect size 
calculator. The calculator used for these computations was the Practical Meta-Analysis 
Effect Size Calculator, developed by David B. Wilson (Wilson, 2018).  The effect sizes 
and variances were recorded and organized into a final table according to the coding 
chiefly for samples and noting scales and scale items. The scale direction for each effect 
size was adjusted to reflect a positive effect size to indicate an increase in negative mood 
symptoms (i.e. worsening of mood), and a negative effect size to indicate a decrease in 
negative mood symptom (i.e. improvement of mood). 
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Figure 1. PRISMA flow chart showing study selection  (Moher, Liberati, Tetzlaff, & 
Altman, 2009). 
Figure 1. PRISMA flow chart showing study selection  (Moher, Liberati, Tetzlaff, & 
Altman, 2009). 
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Results 
A total of 17 different studies contributed data to the final analysis. These studies 
reflect the responses of 1268 participants from 25 unique samples. Taking into account 
the data points contributed by multiple scales or scale items, there were a total of 71 
effect sizes that contributed to the final meta-analysis. 
Since most of the samples included in this analysis contributed multiple effect 
sizes, these data did not meet the assumption of independence of effect sizes, which is a 
necessary prerequisite for most meta-analytic approaches (Gleser & Olkin, 2009). 
Consequently, the choice was made to use robust variance estimation (RVE), which is a 
way of achieving accurate estimation in meta-analysis when dependency is an issue 
(Hedges, Tipton, & Johnson, 2010). RVE produces the best results when used in meta-
analyses that examine at least 40 samples but can still be accurate for analyses that 
include 20-40 samples. In light of this, the Robumeta package for R was used to run the 
analysis, since it allows adjustments for small sample sizes. (Fisher & Tipton, 2015). 
To perform RVE, an initial estimate of the average within-sample correlation 
between effect sizes (designated Rho) must be made. This analysis used an initial 
estimate Rho value of .80, and then a sensitivity analysis was performed to determine the 
stability of this estimate. The sensitivity analysis produced outcomes using Rho values of 
.00, .20, .40, .60, and 1.0 for comparison, and the results of each were the same, 
suggesting a stable estimate. 
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The results suggest that COCs have a small, but significant, positive effect on 
women’s mood (mean ES = -0.54, 95%CI [-1.0200, -0.0479]). As mentioned previously, 
the negative direction of the effect indicates that women tend to experience improvement 
of mood when taking COCs compared to not taking them. 
 
Discussion 
These findings suggest that, in contrast to commonly held ideas about COCs 
creating mood issues, they are more likely to stabilize or improve a woman’s mood when 
she begins taking them. Considering the existing research that focused on using COCs as 
a treatment for PMDD, this result is not overly surprising. However, the variability 
among study methodologies still makes it difficult for researchers to draw strong 
conclusions about the overall effects of COCs on women’s moods. Rather than the 
statistical results obtained from this meta-analysis, the greater takeaway from this 
research is that the field of study regarding COCs and women’s moods is still suffering 
from a lack of standardization in terms of study design, scales, recording of data, and 
definition of variables. Each individual study produced a result, but this information is 
not useful unless it can be considered as a whole with other studies performing the same 
type of research. 
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Limitations 
The small number of studies available to include in this analysis suggests that the 
results may be less accurate than if there had been more data to analyze. It is unclear 
whether publication bias plays a role in these results, although many of the studies 
published non-significant results or simply included the mood scores as secondary 
analyses, suggesting that the current literature reflects an accurate picture of the research 
conducted. Attempts were made to obtain additional data from researchers in the field as 
well, with few contributions, which supports this idea. However, it is also possible that 
clinical trials conducted by pharmaceutical companies were not published, since these 
companies may have a lower incentive to publish research than academic researchers do. 
There is also a possibility that the studies that were excluded due to data issues 
could have contributed to the final analysis in a way that would have affected the 
outcome. Many of the researchers contacted to request data reported that they no longer 
had access to the data for the studies in question. Perhaps if data from all the studies that 
met the criteria for inclusion could have been obtained in a usable format, the results 
might have been different. 
Finally, it is worth mentioning that many of the studies included in the meta-
analysis utilized samples of women suffering from PMDD and focused on using COCs 
containing drospirenone to treat their condition. The aim of this meta-analysis was to 
determine the effects of COCs on an average woman of reproductive age, taking any 
common formulation of COC. While drospirenone-containing COCs in particular may 
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improve women’s moods, especially women who suffer from PMDD, it is possible that 
the inclusion of so many studies examining this formulation of COC using this 
population could have affected the results to show a more positive effect of COCs on 
women’s mood than would be typically expected in a more generalized population. 
Methodological Recommendations 
 The variations in the types of methodologies used to analyze COC use and mood 
is a major contributing factor to the difficulty in drawing any large-scale conclusions 
about COCs and mood effects. This meta-analysis helped to reveal the range of different 
methodologies that are used in this field, as well as their strengths and weaknesses. 
Consequently, there are some recommendations to future researchers about the best types 
of methodologies to use in order to draw stronger and more compelling conclusions about 
the roles of COCs in women’s mood changes. 
Study design. One of the major reasons why studies were excluded from this 
meta-analysis was because the methodology did not allow for comparisons before and 
after women began taking COCs. Some studies used a correlational design, asking 
women if they were taking contraceptives or not, and whether they had experienced 
symptoms of mood worsening. Other studies only compared groups of women taking 
different types of COCs, or women taking them vs. not taking them, without recording 
pre- and post-measurements of mood. These types of methodologies do not allow 
researchers to establish any sort of temporal precedence to show that the worsening of 
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mood could be attributed to the use of COCs, rather than some other outside variable. It is 
recommended that any future studies utilize a design that examines women’s moods 
before using COCs, and again during their use. 
Baseline measurements. While some studies simply administered a 
questionnaire immediately before the initiation of COC use, others chose to track 
women’s moods for a month to collect baseline data. This latter method is preferred since 
it is more comprehensive, providing researchers with a clearer picture of each woman’s 
“average” moods throughout a month. This is especially important considering that 
moods can fluctuate on a daily basis as well as alongside the different phases of a 
woman’s menstrual cycle. It is recommended that future studies collect participants’ 
baseline mood data for at least one month before initiating COC use. For an even more 
fine-tuned approach, researchers could opt to collect baseline date for several months 
beforehand, which would be most useful when establishing average moods as related to 
different phases of a woman’s menstrual cycle. 
Long-term assessments. In the same sense that several baseline measurements 
can provide a clearer picture of women’s average moods before taking COCs, several 
post-pill assessments can help to show the effects of COCs with more accuracy, 
especially when looking at different phases of the menstrual cycle. Some studies perform 
several follow-up assessments of mood for a year or more, which would be ideal for 
examining the long-term effects of COCs on women’s emotional health. These longer-
term assessments would also be useful for studies examining cycle phases in addition to 
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overall effects of COCs. It is recommended that researchers assess women’s moods in the 
first month after beginning COCs, and then make at least two or three future assessments 
for at least six months after the initiation of COCs, ideally more assessments over a 
longer period of time. 
Comparison groups. It remains a methodological challenge for researchers to 
design studies that include a comparison group receiving a placebo, especially if blinding 
is included. To expect a group of healthy women to take a pill for months on end without 
knowing whether it is truly protecting them against pregnancy is a lot to ask of study 
participants, which is why so few studies exist with this type of methodology. Still, it is 
recommended that researchers use a double-blinded placebo-controlled methodology 
whenever possible to avoid concerns about validity due to a placebo effect. Failing this, a 
methodology that utilizes a pre-post design with a non-blinded placebo group is 
preferable for drawing conclusions about the mood effects of COCs, since it will still 
allow for comparisons between mood scores of women who begin taking COCs and 
women who do not. It is recommended that all studies include a comparison group of 
women who take a placebo COC or do not start taking COCs at all, even when studies are 
examining the effects of more than one type of COC. 
Population samples. As mentioned previously, much of the existing research 
examining the mood-related effects of COCs has been conducted using women with 
PMDD. While this itself is an important area of study, it would also be beneficial to 
conduct more clinical trials using healthy women as a sample, or a combination of 
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healthy women and women with varying degrees of pre-existing mental health 
conditions. If the goal is to determine how an average woman’s moods will respond to 
COCs, it makes sense to test this effect in a broader population sample to improve the 
generalizability of research results. 
Types of scales. While it can be useful for researchers to use several types of 
scales to assess measures of mood, it would be advisable for them to include at least one 
measure that conducts daily ratings of moods, such as the DRSP, in addition to broader 
measures, such as the BDI or MADRS.  Ideally, researchers should either develop or 
agree upon a standard scale to use for this type of research to maintain the highest level 
of consistency across studies. It is least advisable for studies to utilize self-made 
questionnaires, as these make it the most difficult to draw broader conclusions and can 
call into question the validity of their measurements. 
 With all of these considerations in mind, it seems that the most beneficial types of 
COC studies would be ones undertaken using a large, representative sample and executed 
over the course of a long timeline. These studies would ideally measure women’s moods 
for a month or more before initiation of COCs, and then for several months after. They 
would also utilize standard scales with at least one prospective daily mood measurement. 
 
Conclusions 
When examining the literature related to COC use and mood, it quickly becomes 
clear that there is not a simple answer to the question that can apply to every woman, but 
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it is also clear that more standardized research methods could help researchers to 
effectively examine factors influencing interactions between COC use and mood. 
Researching the effects of COCs on women’s mood is a tricky task, but not an 
impossible one. At present, it appears that COCs are more likely to improve a woman’s 
moods when she begins taking them than they are to worsen them. However, future 
research conducted in a more standardized way could help to either correct or reinforce 
these results with less ambiguity. In general, a greater number of studies would help to 
create a clearer picture of this effect. This is a worthwhile field of research to continue 
forward with, since so many women currently take COCs and so many more will likely 
begin taking them. 
At present, women who wish to begin taking an oral contraceptive are typically 
prescribed a common formulation of COC and told by their doctors to report any negative 
side effects. If the side effects are severe enough, women are advised to switch to a 
different type of pill or discontinue COC use altogether. However, research efforts could 
aim to draw connections between variables that may work together to contribute to 
changes in mood, and thereby better inform women of which types of birth control may 
be best for an individual’s circumstances prior to use. With more knowledge, women will 
be able to begin taking COCs with more confidence about what side effects they can 
expect to experience and may even be encouraged to initiate COC use to improve mood 
symptoms.
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Appendix A 
Studies included in the final meta-analysis 
Study 
# 
Authors Year Title 
1 Lundin et al 2017 
Combined oral contraceptive use is associated with both 
improvement and worsening of mood in the different phases 
of the treatment cycle--A double-blind, placebo-controlled 
randomized trial  
2 Gingnell et al 2013 
Oral contraceptive use changes brain activity and mood in 
women with previous negative affect on the pill--A double-
blinded, placebo-controlled randomized trial of a 
levonorgestrel-containing combined oral contraceptive 
3 Ott et al 2008 
The influence of hormonal contraception on mood and sexual 
interest among adolescents 
4 Graham et al 2007 
Does oral contraceptive-induced reduction in free 
testosterone adversely affect the sexuality or mood of 
women? 
5 Greco et al 2007 
The effects of oral contraceptives on androgen levels and 
their relevance to the premenstrual mood and sexual interest: 
A comparison of two triphasic formulations containing 
norgestimate and either 35 or 25 μg of ethinyl estradiol 
6 O’Connell et al 2007 
Oral contraceptives: Side effects and depression in adolescent 
girls 
7 Borges et al 2006 
Effect of a combination of ethinylestradiol 30 μg and 
drospirenone 3 mg on tolerance, cycle control, general well-
being and fluid-related symptoms in women with 
premenstrual disorders requesting contraception 
8 Pearlstein et al 2005 
Treatment of premenstrual dysphoric disorder with a new 
drospirenone-containing oral contraceptive formulation 
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9 
Sangthawan & 
Taneepanichskul 
2005 
A comparative study of monophasic oral contraceptives 
containing either drospirenone 3 mg or levonorgestrel 150 μg 
on premenstrual symptoms 
10 Yonkers et al 2005 
Efficacy of a new low-dose oral contraceptive with 
drospirenone in premenstrual dysphoric disorder 
11 Li et al 2004 
Impact of common contraceptive methods on quality of life 
and sexual function in Hong Kong Chinese women 
12 Cinar et al 2012 
Effect of an oral contraceptive on emotional distress, anxiety 
and depression of women with polycystic ovary syndrome: A 
prospective study 
13 Rapkin et al 2006 
Decreased neuroactive steroids induced by combined oral 
contraceptive pills are not associated with mood changes 
14 
Eisenlohr-Moul 
et al 
2017 
Treatment of premenstrual dysphoria with continuous versus 
intermittent dosing of oral contraceptives: Results of a three-
arm randomized controlled trial. 
15 Nyberg et al 2013 
Mood and physical symptoms improve in women with severe 
cyclical changes by taking an oral contraceptive containing 
250-mcg norgestimate and 35-mcg ethinyl estradiol. 
16 Shanazi et al 2014 
A comparison of second and third generations combined oral 
contraceptive pills' effect on mood. 
17 Hahn & Jones 2016 
OCMATE: Oral contraceptives and mate preferences project. 
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